nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—Polydipsia—Furosemide—dilated cardiomyopathy	0.037	0.0489	CcSEcCtD
Fosaprepitant—Hypovolaemia—Furosemide—dilated cardiomyopathy	0.037	0.0489	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—SCN5A—dilated cardiomyopathy	0.0208	0.0858	CbGpPWpGaD
Fosaprepitant—Lethargy—Spironolactone—dilated cardiomyopathy	0.0156	0.0206	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.0148	0.0611	CbGpPWpGaD
Fosaprepitant—Glycosuria—Furosemide—dilated cardiomyopathy	0.0142	0.0187	CcSEcCtD
Fosaprepitant—TACR1—Peptide GPCRs—AGTR2—dilated cardiomyopathy	0.0141	0.0583	CbGpPWpGaD
Fosaprepitant—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.0138	0.0182	CcSEcCtD
Fosaprepitant—TACR1—Peptide GPCRs—CXCR3—dilated cardiomyopathy	0.0131	0.0542	CbGpPWpGaD
Fosaprepitant—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.0117	0.0154	CcSEcCtD
Fosaprepitant—TACR1—Peptide GPCRs—AGTR1—dilated cardiomyopathy	0.0109	0.0448	CbGpPWpGaD
Fosaprepitant—Urine output increased—Furosemide—dilated cardiomyopathy	0.0104	0.0137	CcSEcCtD
Fosaprepitant—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.01	0.0132	CcSEcCtD
Fosaprepitant—Chest discomfort—Lisinopril—dilated cardiomyopathy	0.00973	0.0128	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—CXCL2—dilated cardiomyopathy	0.00973	0.0401	CbGpPWpGaD
Fosaprepitant—Thrombophlebitis—Furosemide—dilated cardiomyopathy	0.00963	0.0127	CcSEcCtD
Fosaprepitant—Oropharyngeal pain—Lisinopril—dilated cardiomyopathy	0.00947	0.0125	CcSEcCtD
Fosaprepitant—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00887	0.0117	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00856	0.0113	CcSEcCtD
Fosaprepitant—Lethargy—Furosemide—dilated cardiomyopathy	0.0085	0.0112	CcSEcCtD
Fosaprepitant—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00837	0.011	CcSEcCtD
Fosaprepitant—Wheezing—Lisinopril—dilated cardiomyopathy	0.00836	0.011	CcSEcCtD
Fosaprepitant—Malaise—Spironolactone—dilated cardiomyopathy	0.00832	0.011	CcSEcCtD
Fosaprepitant—Discomfort—Spironolactone—dilated cardiomyopathy	0.00776	0.0102	CcSEcCtD
Fosaprepitant—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00758	0.01	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00753	0.00994	CcSEcCtD
Fosaprepitant—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.0075	0.0099	CcSEcCtD
Fosaprepitant—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00735	0.0097	CcSEcCtD
Fosaprepitant—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00725	0.00957	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—GJA1—dilated cardiomyopathy	0.00723	0.0298	CbGpPWpGaD
Fosaprepitant—Somnolence—Spironolactone—dilated cardiomyopathy	0.00669	0.00883	CcSEcCtD
Fosaprepitant—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00665	0.00878	CcSEcCtD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—AGTR2—dilated cardiomyopathy	0.00665	0.0274	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CXCL2—dilated cardiomyopathy	0.00665	0.0274	CbGpPWpGaD
Fosaprepitant—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00657	0.00868	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.0065	0.00858	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00637	0.0084	CcSEcCtD
Fosaprepitant—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00628	0.00829	CcSEcCtD
Fosaprepitant—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00625	0.00825	CcSEcCtD
Fosaprepitant—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.0062	0.00819	CcSEcCtD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CXCR3—dilated cardiomyopathy	0.00618	0.0255	CbGpPWpGaD
Fosaprepitant—Urticaria—Spironolactone—dilated cardiomyopathy	0.00598	0.00789	CcSEcCtD
Fosaprepitant—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00595	0.00785	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.00578	0.0239	CbGpPWpGaD
Fosaprepitant—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00569	0.00751	CcSEcCtD
Fosaprepitant—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00565	0.00746	CcSEcCtD
Fosaprepitant—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.00563	0.00743	CcSEcCtD
Fosaprepitant—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00555	0.00732	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—RAC1—dilated cardiomyopathy	0.00551	0.0227	CbGpPWpGaD
Fosaprepitant—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00545	0.00719	CcSEcCtD
Fosaprepitant—Eye disorder—Furosemide—dilated cardiomyopathy	0.00539	0.00711	CcSEcCtD
Fosaprepitant—Tinnitus—Furosemide—dilated cardiomyopathy	0.00537	0.00709	CcSEcCtD
Fosaprepitant—Pruritus—Spironolactone—dilated cardiomyopathy	0.00533	0.00703	CcSEcCtD
Fosaprepitant—Angiopathy—Furosemide—dilated cardiomyopathy	0.00523	0.0069	CcSEcCtD
Fosaprepitant—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00521	0.00687	CcSEcCtD
Fosaprepitant—TACR1—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.00518	0.0214	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00515	0.0068	CcSEcCtD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—AGTR1—dilated cardiomyopathy	0.00511	0.0211	CbGpPWpGaD
Fosaprepitant—Dysuria—Lisinopril—dilated cardiomyopathy	0.00505	0.00667	CcSEcCtD
Fosaprepitant—Malnutrition—Furosemide—dilated cardiomyopathy	0.00502	0.00662	CcSEcCtD
Fosaprepitant—Erythema—Furosemide—dilated cardiomyopathy	0.00502	0.00662	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.00501	0.0207	CbGpPWpGaD
Fosaprepitant—Dizziness—Spironolactone—dilated cardiomyopathy	0.00498	0.00657	CcSEcCtD
Fosaprepitant—Flatulence—Furosemide—dilated cardiomyopathy	0.00495	0.00653	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00493	0.00651	CcSEcCtD
Fosaprepitant—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00491	0.00649	CcSEcCtD
Fosaprepitant—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00489	0.00645	CcSEcCtD
Fosaprepitant—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00482	0.00637	CcSEcCtD
Fosaprepitant—Vomiting—Spironolactone—dilated cardiomyopathy	0.00479	0.00632	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00478	0.0063	CcSEcCtD
Fosaprepitant—Rash—Spironolactone—dilated cardiomyopathy	0.00475	0.00626	CcSEcCtD
Fosaprepitant—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00474	0.00626	CcSEcCtD
Fosaprepitant—Headache—Spironolactone—dilated cardiomyopathy	0.00472	0.00622	CcSEcCtD
Fosaprepitant—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00468	0.00618	CcSEcCtD
Fosaprepitant—Anaemia—Furosemide—dilated cardiomyopathy	0.00464	0.00612	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.00463	0.0191	CbGpPWpGaD
Fosaprepitant—Haematuria—Lisinopril—dilated cardiomyopathy	0.00459	0.00606	CcSEcCtD
Fosaprepitant—Nausea—Spironolactone—dilated cardiomyopathy	0.00447	0.0059	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00446	0.0184	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00446	0.0184	CbGpPWpGaD
Fosaprepitant—Bradycardia—Lisinopril—dilated cardiomyopathy	0.0044	0.00581	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00427	0.00564	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00424	0.0056	CcSEcCtD
Fosaprepitant—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00424	0.0056	CcSEcCtD
Fosaprepitant—Dry mouth—Furosemide—dilated cardiomyopathy	0.00418	0.00551	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00414	0.0171	CbGpPWpGaD
Fosaprepitant—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.0041	0.00541	CcSEcCtD
Fosaprepitant—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00409	0.0054	CcSEcCtD
Fosaprepitant—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00403	0.00532	CcSEcCtD
Fosaprepitant—Shock—Furosemide—dilated cardiomyopathy	0.00403	0.00532	CcSEcCtD
Fosaprepitant—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00402	0.0053	CcSEcCtD
Fosaprepitant—Flushing—Lisinopril—dilated cardiomyopathy	0.00401	0.0053	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.00401	0.0166	CbGpPWpGaD
Fosaprepitant—Skin disorder—Furosemide—dilated cardiomyopathy	0.00398	0.00525	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00396	0.00523	CcSEcCtD
Fosaprepitant—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00392	0.00518	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.0039	0.00515	CcSEcCtD
Fosaprepitant—Hypotension—Furosemide—dilated cardiomyopathy	0.00383	0.00505	CcSEcCtD
Fosaprepitant—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00379	0.005	CcSEcCtD
Fosaprepitant—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00377	0.00497	CcSEcCtD
Fosaprepitant—Erythema—Lisinopril—dilated cardiomyopathy	0.00377	0.00497	CcSEcCtD
Fosaprepitant—Flatulence—Lisinopril—dilated cardiomyopathy	0.00371	0.0049	CcSEcCtD
Fosaprepitant—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00369	0.00487	CcSEcCtD
Fosaprepitant—TACR1—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.00364	0.015	CbGpPWpGaD
Fosaprepitant—Somnolence—Furosemide—dilated cardiomyopathy	0.00364	0.00481	CcSEcCtD
Fosaprepitant—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00362	0.00478	CcSEcCtD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.0036	0.0148	CbGpPWpGaD
Fosaprepitant—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00356	0.0047	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00354	0.00467	CcSEcCtD
Fosaprepitant—Fatigue—Furosemide—dilated cardiomyopathy	0.00353	0.00466	CcSEcCtD
Fosaprepitant—Constipation—Furosemide—dilated cardiomyopathy	0.0035	0.00462	CcSEcCtD
Fosaprepitant—Pain—Furosemide—dilated cardiomyopathy	0.0035	0.00462	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00349	0.00461	CcSEcCtD
Fosaprepitant—Anaemia—Lisinopril—dilated cardiomyopathy	0.00348	0.00459	CcSEcCtD
Fosaprepitant—Angioedema—Lisinopril—dilated cardiomyopathy	0.00344	0.00454	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.00343	0.0141	CbGpPWpGaD
Fosaprepitant—Malaise—Lisinopril—dilated cardiomyopathy	0.0034	0.00448	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00339	0.014	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00339	0.014	CbGpPWpGaD
Fosaprepitant—Syncope—Lisinopril—dilated cardiomyopathy	0.00338	0.00446	CcSEcCtD
Fosaprepitant—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00338	0.00445	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00335	0.00442	CcSEcCtD
Fosaprepitant—Palpitations—Lisinopril—dilated cardiomyopathy	0.00333	0.00439	CcSEcCtD
Fosaprepitant—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00331	0.00437	CcSEcCtD
Fosaprepitant—Cough—Lisinopril—dilated cardiomyopathy	0.00329	0.00434	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.00326	0.0134	CbGpPWpGaD
Fosaprepitant—Urticaria—Furosemide—dilated cardiomyopathy	0.00325	0.00429	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00325	0.0134	CbGpPWpGaD
Fosaprepitant—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00324	0.00427	CcSEcCtD
Fosaprepitant—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00324	0.00427	CcSEcCtD
Fosaprepitant—Chest pain—Lisinopril—dilated cardiomyopathy	0.00321	0.00423	CcSEcCtD
Fosaprepitant—Anxiety—Lisinopril—dilated cardiomyopathy	0.00319	0.00422	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00318	0.0042	CcSEcCtD
Fosaprepitant—Discomfort—Lisinopril—dilated cardiomyopathy	0.00317	0.00418	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.00316	0.013	CbGpPWpGaD
Fosaprepitant—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00314	0.00414	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00307	0.00406	CcSEcCtD
Fosaprepitant—Oedema—Lisinopril—dilated cardiomyopathy	0.00307	0.00406	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.00306	0.0126	CbGpPWpGaD
Fosaprepitant—Infection—Lisinopril—dilated cardiomyopathy	0.00305	0.00403	CcSEcCtD
Fosaprepitant—Shock—Lisinopril—dilated cardiomyopathy	0.00302	0.00399	CcSEcCtD
Fosaprepitant—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00302	0.00398	CcSEcCtD
Fosaprepitant—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00298	0.00394	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00297	0.00392	CcSEcCtD
Fosaprepitant—Asthenia—Furosemide—dilated cardiomyopathy	0.00294	0.00388	CcSEcCtD
Fosaprepitant—Pruritus—Furosemide—dilated cardiomyopathy	0.0029	0.00382	CcSEcCtD
Fosaprepitant—Hypotension—Lisinopril—dilated cardiomyopathy	0.00287	0.00379	CcSEcCtD
Fosaprepitant—Diarrhoea—Furosemide—dilated cardiomyopathy	0.0028	0.0037	CcSEcCtD
Fosaprepitant—Insomnia—Lisinopril—dilated cardiomyopathy	0.00278	0.00367	CcSEcCtD
Fosaprepitant—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00274	0.00362	CcSEcCtD
Fosaprepitant—Somnolence—Lisinopril—dilated cardiomyopathy	0.00273	0.00361	CcSEcCtD
Fosaprepitant—Dizziness—Furosemide—dilated cardiomyopathy	0.00271	0.00357	CcSEcCtD
Fosaprepitant—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00271	0.00357	CcSEcCtD
Fosaprepitant—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00267	0.00353	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00265	0.0035	CcSEcCtD
Fosaprepitant—Fatigue—Lisinopril—dilated cardiomyopathy	0.00265	0.0035	CcSEcCtD
Fosaprepitant—Pain—Lisinopril—dilated cardiomyopathy	0.00263	0.00347	CcSEcCtD
Fosaprepitant—Constipation—Lisinopril—dilated cardiomyopathy	0.00263	0.00347	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.00261	0.0108	CbGpPWpGaD
Fosaprepitant—Vomiting—Furosemide—dilated cardiomyopathy	0.0026	0.00344	CcSEcCtD
Fosaprepitant—Rash—Furosemide—dilated cardiomyopathy	0.00258	0.00341	CcSEcCtD
Fosaprepitant—Dermatitis—Furosemide—dilated cardiomyopathy	0.00258	0.00341	CcSEcCtD
Fosaprepitant—Headache—Furosemide—dilated cardiomyopathy	0.00257	0.00339	CcSEcCtD
Fosaprepitant—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00253	0.00334	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00251	0.00332	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—EGFR—dilated cardiomyopathy	0.00251	0.0103	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.00248	0.0102	CbGpPWpGaD
Fosaprepitant—Urticaria—Lisinopril—dilated cardiomyopathy	0.00244	0.00322	CcSEcCtD
Fosaprepitant—Nausea—Furosemide—dilated cardiomyopathy	0.00243	0.00321	CcSEcCtD
Fosaprepitant—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00243	0.00321	CcSEcCtD
Fosaprepitant—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00243	0.00321	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.00241	0.00995	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—TNF—dilated cardiomyopathy	0.00239	0.00984	CbGpPWpGaD
Fosaprepitant—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00226	0.00299	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.00226	0.00933	CbGpPWpGaD
Fosaprepitant—Asthenia—Lisinopril—dilated cardiomyopathy	0.0022	0.00291	CcSEcCtD
Fosaprepitant—Pruritus—Lisinopril—dilated cardiomyopathy	0.00217	0.00287	CcSEcCtD
Fosaprepitant—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.0021	0.00278	CcSEcCtD
Fosaprepitant—Dizziness—Lisinopril—dilated cardiomyopathy	0.00203	0.00268	CcSEcCtD
Fosaprepitant—Vomiting—Lisinopril—dilated cardiomyopathy	0.00195	0.00258	CcSEcCtD
Fosaprepitant—Rash—Lisinopril—dilated cardiomyopathy	0.00194	0.00256	CcSEcCtD
Fosaprepitant—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00194	0.00255	CcSEcCtD
Fosaprepitant—Headache—Lisinopril—dilated cardiomyopathy	0.00193	0.00254	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.00192	0.00792	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.00192	0.00792	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.00191	0.00787	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.00184	0.00758	CbGpPWpGaD
Fosaprepitant—Nausea—Lisinopril—dilated cardiomyopathy	0.00183	0.00241	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.00178	0.00736	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.00174	0.00719	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.00174	0.00719	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.00173	0.00713	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.00162	0.00668	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.00157	0.00647	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.00155	0.0064	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.00148	0.00609	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.0014	0.00577	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.00134	0.00553	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.00127	0.00524	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.00116	0.00478	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.00109	0.00448	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.00104	0.00428	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.00103	0.00425	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.00103	0.00425	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000987	0.00407	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000957	0.00395	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000943	0.00389	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000926	0.00382	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000791	0.00327	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000751	0.0031	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000654	0.0027	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000645	0.00266	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000583	0.0024	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AGT—dilated cardiomyopathy	0.000557	0.0023	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000449	0.00185	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000386	0.00159	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EGFR—dilated cardiomyopathy	0.000265	0.00109	CbGpPWpGaD
